Third Rock Ventures
Ejecutivos
Ver el organigrama con sus 35 ejecutivos principales
Biografías más buscadas en Third Rock Ventures
- Abbie Celniker, Partner, Formation, Development and Strategy
- Chris Robinson, Chief Talent Officer
- Neil Exter, Partner, Formation, Development and Strategy
Recientes movimientos de ejecutivos en Third Rock Ventures
- Courtney Wallace, se ha incorporado a la empresa como Venture Partner (noticia publicada el 26 de enero de 2024).
- Jigar Raythatha que ha sido Venture Partner, ha ascendido a Partner (noticia publicada el 26 de enero de 2024).
- Vyas Ramanan que ha sido Principal, ha ascendido a Venture Partner (noticia publicada el 26 de enero de 2024).
Haga clic aquí para ver otros movimientos en Third Rock Ventures
Crear su alerta
para seguir los movimientos de los ejecutivos en Third Rock Ventures.
Fondo
Third Rock Ventures tiene 1.475 competidores entre los que se incluyen Lloyds Development Capital (Reino Unido), BlackRock (Estados Unidos) y WindRose Health Investors (Estados Unidos).
Popular M&A news in Fondo
- Abrdn Private Equity Opportunities Trust cambiará su nombre a Patria Capital Partners. (publicado el 30 de abril de 2024).
- HMC Capital ha StratCap adquirido (publicado el 28 de febrero de 2024).
- Thomvest Ventures acaba de anunciar una recaudación de fondos de 250 millones de dólares. (publicado el 17 de enero de 2024).
Otros contactos sugeridos en el sector Fondo
- Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer en Valor Equity Partners
- Mortimer Buckley - Chairman of the Board and Chief Executive Officer (retiring in Dec 2024) en Vanguard
- Jean-Marc Arbaud - President and Chief Executive Officer of CDPQ Infra en Caisse de Dépôt et Placement du Québec
Noticias
Últimos comunicados de prensa de Third Rock Ventures
- Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024 | Tango Therapeutics, Inc
- Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis | Pliant Therapeutics, Inc.
- Septerna Appoints Industry Veterans Bernard Coulie, M.D., Ph.D., and Shalini Sharp to its Board of Directors - Septerna
- Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis | Pliant Therapeutics, Inc.
- CARGO Therapeutics Announces Pricing of Initial Public Offering | CARGO Therapeutics, Inc.
- Terremoto Biosciences Closes $175 Million Series B Financing | Terremoto
- Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
- Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023 | Pliant Therapeutics, Inc.
- Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer | Pliant Therapeutics, Inc.
- Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) | Fulcrum Therapeutics
- View more press releases Close
Redes sociales sobre Third Rock Ventures
- Third Rock Ventures en Wikipedia, Google News y Yahoo Finance
- Third Rock Ventures en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Alison Connors 
Llame a Third Rock Ventures al +1 617...
